Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02142712 · ClinicalTrials.gov registry record · Phase 2
Histamine Glutamate Antagonism in Stroke
A Phase 2 study of Cerebral Edema and Acute Cerebrovascular Accident, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02142712 is a Phase 2 study of Cerebral Edema and Acute Cerebrovascular Accident that has completed, run by University of Florida. The registered enrollment target is 3 participants, below the 247-participant average among 3 other Cerebral Edema trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02142712, a Phase 2 study of Cerebral Edema and Acute Cerebrovascular Accident, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Stroke is the 4th leading cause of death in United States with an estimated 1 death every 4 minutes. On average, someone suffers from stroke in United States every 40th second. Stroke recurs in 1 out of 4 stroke patients. About 87% of the strokes are as a result of ischemic insult. The total economic burden from stroke accounts to 38.6 billion dollars per year. Stroke is also one of the leading causes of long term disability. Current stroke therapies concentrate mainly on acute revascularization, sub-acute rehabilitation and secondary prevention. Neuroprotection is not the mainstay of treatment modality as there are no effective regimen which has satisfied stroke clinicians and researchers. Many neuroprotection agents have shown excellent pre-clinical results but have failed in clinical translation. Thus we need to find new treatments in order to decrease the mortality and morbidity caused by stroke. The investigators hypothesize that adopting a narrower therapeutic window, with treatment initiation in the first six hours, may demonstrate a positive or significant short and long term neuroprotective effect from NMDA/Glutaminergic or histaminergic antagonism when compared with standard of care.
Conditions Studied
Interventions
- DRUG Diphenhydramine
- DRUG Famotidine
- DRUG Dextromethorphan
- DRUG Pantoprazole
Study Locations (1)
Florida
- Shands Hospital at University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02142712
The ClinicalTrials.gov registry entry for NCT02142712 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 247-participant average among 3 other Cerebral Edema trials with a reported enrollment target (99% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cerebral Edema appearing as the primary indexed condition, and to 4 interventions - of which Diphenhydramine is the first listed.
NCT02142712 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02142712 about?
NCT02142712 is a clinical study titled "Histamine Glutamate Antagonism in Stroke". Stroke is the 4th leading cause of death in United States with an estimated 1 death every 4 minutes. On average, someone suffers from stroke in United States every 40th second. Stroke recurs in 1 out of 4 stroke patients. About 87% of the strokes are as a result of ischemic insult. The total economi...
What is the current status of trial NCT02142712?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-12. Estimated completion is 2014-12.
What conditions does trial NCT02142712 study?
This clinical trial studies the following conditions: Cerebral Edema, Acute Cerebrovascular Accident.
What interventions are being tested in trial NCT02142712?
The interventions under investigation include: Diphenhydramine (DRUG), Famotidine (DRUG), Dextromethorphan (DRUG), Pantoprazole (DRUG).
Who is sponsoring clinical trial NCT02142712?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02142712 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access
COMPLETED · Phase 2
-
Implementation of Neuro Lung Protective Ventilation
ACTIVE NOT RECRUITING · NA
-
Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.